Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
Journal of Clinical Oncology · 20.03.2024 · 42 (9) · 1021-1030
DOI: 10.1200/jco.23.01498 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2024. Verfasst von Glenn J Hanna und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Skin Neoplasms, Carcinoma, Squamous Cell, Kidney Transplantation, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
PURPOSE Cemiplimab is approved for treating locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). Solid organ transplant recipients have been excluded from immunotherapy trials, given concern for allograft rejection despite their increased risk of skin cancers. Chronic immunosuppression is necessary to prevent organ rejection but may attenuate antitumor response with PD-1 inhibitors. METHODS We report a phase I study of cemiplimab for kidney transplant recipients (KTRs) with advanced CSCC. After cross-taper to a mammalian target of rapamycin (mTOR) inhibitor and pulsed dose corticosteroids (prednisone 40 mg once daily, the day before and on days 1-3 of each cycle, followed by 20 mg once daily on days 4-6, then 10 mg once daily until the day before each subsequent cycle), patients received cemiplimab 350 mg intravenously once every 3 weeks for up to 2 years and were assessed for response every 8 weeks. The primary end point was the rate of kidney rejection, with key secondary end points including rate and duration of response, and survival. RESULTS Twelve patients were treated. No kidney rejection or loss was observed. A response to cemiplimab was observed in five of 11 evaluable patients (46%; 90% CI, 22 to 73), including two with durable responses beyond a year. Median follow-up was 6.8 months (range, 0.7-29.8). Treatment-related grade 3 or greater adverse events occurred in five patients (42%), including diarrhea, infection, and metabolic disturbances. One patient died of angioedema and anaphylaxis attributed to mTOR inhibitor cross-taper. CONCLUSION mTOR inhibitor and corticosteroids represent a favorable immunosuppressive regimen for KTRs with advanced CSCC receiving immunotherapy. This combination resulted in durable antitumor responses with no kidney rejection events (funded by Regeneron Pharmaceuticals [ClinicalTrials.gov identifier: NCT04339062 ]).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
- Department of Hematology/Oncology, Tufts Medical Center, Boston, MA.
- Department of Hematology/Oncology, Maine Health Cancer Center, Portland, ME.
- Department of Medicine, Renal Division, Massachusetts General Hospital, Boston, MA.
ORCID-Profile: Glenn J Hanna, Harita Dharanesswaran, Anita Giobbie-Hurder, Vatche Tchekmedyian, Emily S Ruiz, Chrysalyne D Schmults, Leonardo V Riella, Patrick Lizotte, Naoka Murakami, Ann W Silk
Förderung
- NIDDK NIH HHS
Zitieren
APA
Hanna, G. J., Dharanesswaran, H., Giobbie-Hurder, A., Harran, J. J., Liao, Z., Pai, L., Tchekmedyian, V., Ruiz, E. S., Waldman, A. H., Schmults, C. D., Riella, L. V., Lizotte, P., Paweletz, C. P., Chandraker, A. K., Murakami, N., & Silk, A. W. (2024). Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma. Journal of Clinical Oncology, 42(9), 1021-1030. https://doi.org/10.1200/jco.23.01498
Vancouver
Hanna GJ, Dharanesswaran H, Giobbie-Hurder A, Harran JJ, Liao Z, Pai L, et al. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma. Journal of Clinical Oncology. 2024;42(9):1021-1030. doi:10.1200/jco.23.01498
BibTeX
@article{Hanna2024,
author = {Hanna, Glenn J and Dharanesswaran, Harita and Giobbie-Hurder, Anita and Harran, John J and Liao, Zixi and Pai, Lori and Tchekmedyian, Vatche and Ruiz, Emily S and Waldman, Abigail H and Schmults, Chrysalyne D and Riella, Leonardo V and Lizotte, Patrick and Paweletz, Cloud P and Chandraker, Anil K and Murakami, Naoka and Silk, Ann W},
title = {Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {9},
pages = {1021--1030},
doi = {10.1200/jco.23.01498}
}
EUVIMED